Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus CLOBETASOL PROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus CLOBETASOL PROPIONATE.
ARAZLO vs CLOBETASOL PROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines and suppression of immune response via modulation of gene expression.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply topically as a thin film to affected areas once to twice daily. Maximum 50 g/week. Treatment duration not to exceed 2 consecutive weeks.
None Documented
None Documented
Clinical Note
moderateClobetasol propionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gatifloxacin."
Clinical Note
moderateClobetasol propionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rosoxacin."
Clinical Note
moderateClobetasol propionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Levofloxacin."
Clinical Note
moderateTerminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life is approximately 2-3 hours after topical application. However, due to prolonged cutaneous retention, clinical effects may persist beyond systemic elimination.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily fecal (biliary) with minimal renal excretion. Less than 5% of a topical dose is recovered in urine as metabolites; the majority is eliminated via feces after hepatic metabolism.
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid
Clobetasol propionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Trovafloxacin."